Go Pro
OTCMKTS:AUGX

Augmedix (AUGX) Stock Price, News & Analysis

Augmedix logo
$2.35 0.00 (0.00%)
As of 10/2/2024

About Augmedix Stock (OTCMKTS:AUGX)

Key Stats

Today's Range
$2.35
$2.35
50-Day Range
$2.35
$2.35
52-Week Range
$0.73
$6.25
Volume
N/A
Average Volume
635,746 shs
Market Capitalization
$115.07 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
Consensus Rating
N/A

Company Overview

Augmedix is a healthcare technology company that specializes in providing real‐time clinical documentation solutions for physicians. Using a combination of cloud-based software and specially trained remote medical scribes, the company captures and converts physician-patient encounters into structured electronic health records (EHR) notes. This service is designed to streamline workflow, reduce administrative burden for clinicians and allow more time for direct patient care.

The company’s core offering revolves around its Augmedix Platform, which integrates with leading EHR systems to deliver seamless data capture. Through secure audio and video streaming, remote scribes listen in on live patient visits and populate clinical documentation in real time. Augmedix also offers complementary tools such as mobile and tablet applications that enable on-the-go access to patient records, telehealth support and analytics dashboards for practice performance monitoring.

Founded in 2012 and headquartered in San Francisco, Augmedix was an early adopter of wearable technology, initially leveraging devices like Google Glass to facilitate doctor-scribe interactions. Co-founders Ian Shakil (who serves as Chief Executive Officer) and Pelu Tran (Chief Operating Officer) have guided the company’s expansion into multiple U.S. states as well as international markets, including the United Kingdom and Canada. The leadership team comprises professionals with deep experience in healthcare operations, technology development and clinical workflow optimization.

Augmedix partners with hospitals, health systems and private practices to tailor its documentation services to specific specialties, such as primary care, orthopedics and neurology. By outsourcing the clerical aspects of patient visits, the company helps reduce physician burnout, enhance documentation accuracy and improve patient satisfaction — all while enabling practices to leverage data insights for better operational decision-making.

AI Generated. May Contain Errors.

Receive AUGX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Augmedix and its competitors with MarketBeat's FREE daily newsletter.

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

AUGX Stock News Headlines

Lake Street Downgrades Augmedix (AUGX)
Buy this stock today
Marc Chaikin, founder of Chaikin Analytics, is sharing a strategy he calls 'Sell This, Buy That' - a way to move out of overpriced AI stocks before the tech trade breaks down and into lesser-known names with real potential to challenge the Mag 7. One pick he calls 'an upgrade to Tesla stock' is a little-known company that just inked a partnership with Nvidia, positioning it ahead of Tesla in the autonomous vehicle race.tc pixel
See More Headlines

AUGX Stock Analysis - Frequently Asked Questions

Augmedix's stock was trading at $2.35 at the beginning of the year. Since then, AUGX stock has increased by 0.0% and is now trading at $2.35.

Augmedix, Inc. (OTCMKTS:AUGX) released its earnings results on Monday, March, 27th. The company reported ($0.15) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.16) by $0.01. The company had revenue of $8.75 million for the quarter, compared to analyst estimates of $8.52 million. Augmedix had a negative net margin of 57.70% and a negative trailing twelve-month return on equity of 980.09%.

Shares of AUGX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that Augmedix investors own include Meta Platforms (META), Urban Outfitters (URBN), Arista Networks (ANET), Capital Southwest (CSWC), NVIDIA (NVDA), PACCAR (PCAR) and Turkcell Iletisim Hizmetleri AS (TKC).

Company Calendar

Last Earnings
3/27/2023
Today
8/12/2026
Fiscal Year End
12/31/2026

Industry, Sector and Symbol

Stock Exchange
OTCMKTS
Industry
Healthcare Technology
Sub-Industry
Healthcare Technology
Current Symbol
OTCMKTS:AUGX
CIK
1769804
Fax
N/A
Employees
710
Year Founded
2012

Profitability

EPS (Trailing Twelve Months)
($0.43)
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
-$24.45 million
Net Margins
-57.70%
Pretax Margin
-57.23%
Return on Equity
-980.09%
Return on Assets
-57.85%

Debt

Debt-to-Equity Ratio
3.74
Current Ratio
1.70
Quick Ratio
1.70

Sales & Book Value

Annual Sales
$51.58 million
Price / Sales
2.23
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
$0.10 per share
Price / Book
23.50

Miscellaneous

Outstanding Shares
48,968,000
Free Float
36,316,000
Market Cap
$115.07 million
Optionable
Not Optionable
Beta
-0.22

Social Links

 The Best Nuclear Energy Stocks to Buy Cover

Nuclear energy is entering a new growth cycle as rising power demand, expanding data centers, and renewed policy support bring the sector back into focus. After strong gains in recent years, the most impactful phase of nuclear investment may still be ahead. This report highlights seven nuclear energy stocks positioned across the value chain—combining near-term revenue with long-term upside as next-generation technologies scale. Click the link below to unlock the full list.

Get This Free Report

This page (OTCMKTS:AUGX) was last updated on 8/12/2026 by MarketBeat.com Staff.
From Our Partners